Related Experiment Video

Updated: Aug 7, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Statin use and cancer risk: an epidemiologic review

Søren Friis1, Jørgen H Olsen

  • 1Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. friis@cancer.dk

Cancer Investigation
|June 17, 2006
PubMed

Insights

Statins, used for cardiovascular health, have uncertain effects on cancer. While some evidence suggests anti-cancer properties, clinical studies show they do not appear carcinogenic, warranting further research.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used for cardiovascular disease.
  • Statins impact the mevalonate pathway, affecting cholesterol and cellular processes.
  • Preclinical data suggest statins may possess antineoplastic properties, but concerns about carcinogenic potential exist.

Purpose of the Study:

  • To evaluate the effects of statins on cancer development and progression.
  • To reconcile conflicting evidence regarding statins' antineoplastic and carcinogenic potential.
  • To identify the need for further research to clarify statins' role in oncology.

Main Methods:

  • Review of preclinical data on statin mechanisms.
  • Analysis of clinical and observational studies on statin use and cancer.
  • Identification of methodological limitations in existing studies.

Main Results:

  • Preclinical studies suggest potential antineoplastic effects of statins.
  • Clinical and observational studies provide reassuring evidence that statins are not carcinogenic.
  • Existing studies are inconclusive regarding chemopreventive or therapeutic effects of statins on cancer.

Conclusions:

  • Statins do not appear to increase cancer risk.
  • Further research, including Phase II trials and robust epidemiological studies, is needed.
  • Clarifying the role of statins in cancer prevention and treatment requires addressing methodological challenges.

More Related Videos

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...